Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Rat dog micro-cap picks... -- Ignore unavailable to you. Want to Upgrade?

To: EVENT HORIZON III who wrote (10712)	2/24/2003 5:54:48 PM
From: EVENT HORIZON III	Respond to of 48463

Ratdog, Would you take a look at ARDM's scenario... I posted a few thoughts at Yahoo... No it's not a now event but definately one which should follow through as anticipated... Looks like a rush order IMO over the next six months based on the manner in which the funding has been setup... IMO they are going to need to move ARDM to between $4 & $7 to move the sort of stock they hold...over the next six to nine months... stockcharts.com Enjoy Jeff

To: EVENT HORIZON III who wrote (10712)	6/14/2003 12:27:14 PM
From: Silver_Bullet	Respond to of 48463

It would have been nice for the real reason to buy ARDM to be presented. That would be the development of a non-injectable(Inhaled) form insulin. Now this is something worth buying. Good call non-the-less. Aradigm shares rise 44 pct on insulin data, report biz.yahoo.com Shares of Aradigm Corp. (NasdaqNM:ARDM - News), which is developing with Danish pharmaceutical group Novo Nordisk (Copenhagen:NOVOb.CO - News) an inhaled form of insulin, rose 44 percent on Friday after an analyst report said the companies will present promising data on the product at a medical meeting. Shares of Aradigm, based in Hayward, California, rose 82 cents to close at $2.68 on Nasdaq. Punk, Ziegel & Co. analyst Matt Kaplan repeated a "buy" recommendation on the stock, citing additional analysis of mid-stage trial data on the AERx pulmonary insulin system that will be presented this weekend at a meeting of the American Diabetes Association in New Orleans. FT